SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG): * REVLIMID® #1 Therapy in Multiple Myeloma Worldwide * European Launch of VIDAZA® Commencing
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG): * REVLIMID® #1 Therapy in Multiple Myeloma Worldwide * European Launch of VIDAZA® Commencing